Correspondence 0001214659-24-014784 from Biodexa Pharmaceuticals Plc (BDRX)
Biodexa Pharmaceuticals Plc
Date: Aug. 15, 2024 · CIK: 0001643918 · Accession: 0001214659-24-014784
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281489
Letter
Biodexa Pharmaceuticals PLC
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ
United Kingdom
August 15, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Tyler Howes
Re: Biodexa Pharmaceuticals PLC
Registration Statement on Form F-1 (File No. 333-281489)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Biodexa Pharmaceuticals PLC (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form F-1 (the “Registration Statement”) and declare the Registration Statement effective as of 4:30 p.m., Eastern Time, on August 19, 2024, or as soon as practicable thereafter.
The Registrant requests that it be notified of such effectiveness by a telephone call to Jason S. McCaffrey of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (617) 348-4416 or by an email to JSMcCaffrey@mintz.com.
Thank you for your assistance. If you should have any questions, please contact Mr. McCaffrey at (617) 348-4416.
Very truly yours,
BIODEXA PHARMACEUTICALS PLC
Show Raw Text
CORRESP
1
filename1.htm
Biodexa Pharmaceuticals PLC
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ
United Kingdom
August 15, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Tyler Howes
Re: Biodexa Pharmaceuticals PLC
Registration Statement on Form F-1 (File No. 333-281489)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules
and Regulations under the Securities Act of 1933, as amended, Biodexa Pharmaceuticals PLC (the “Registrant”) hereby respectfully
requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form
F-1 (the “Registration Statement”) and declare the Registration Statement effective as of 4:30 p.m., Eastern Time, on August
19, 2024, or as soon as practicable thereafter.
The Registrant requests that it be notified
of such effectiveness by a telephone call to Jason S. McCaffrey of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the
Registrant, at (617) 348-4416 or by an email to JSMcCaffrey@mintz.com.
Thank you for your assistance. If you should
have any questions, please contact Mr. McCaffrey at (617) 348-4416.
Very truly yours,
BIODEXA PHARMACEUTICALS PLC
By: /s/ Stephen Stamp
Name: Stephen Stamp
Title: Chief Executive Officer & Chief Financial Officer
cc: Jason S. McCaffrey, Esq., Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C.